PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)

PURPOSE: Triple-negative breast cancer (TNBC) has a poor outcome compared to other subtypes, even in those with early disease. Immune checkpoint inhibitors (ICIs) have been approved in metastatic diseases and are being tested as a neoadjuvant strategy also. The response to ICIs is largely determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Joydeep, Chatterjee, Meheli, Ganguly, Sandip, Datta, Anupurva, Biswas, Bivas, Mukherjee, Geetashree, Agarwal, Sanjit, Ahmed, Rosina, Chatterjee, Sanjoy, Dabkara, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183644/
https://www.ncbi.nlm.nih.gov/pubmed/34158821
http://dx.doi.org/10.3332/ecancer.2021.1217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183644/
https://www.ncbi.nlm.nih.gov/pubmed/34158821
http://dx.doi.org/10.3332/ecancer.2021.1217

Ejemplares similares